ARCHIVES

Extent Of Risk Reduction From Ovary Removal Varies According To BRCA Mutation

This article is from The Cancer Letter archive.

Vol. 31 No. 2 | February 29, 2008

Download PDF Visit The Full Archive

Related Articles

DFA Proposes Controversial Guidelines For Clinical Tests

November 21, 1975

In Brief: All 77 New NCI Positions Go to Carcinogenesis Programs; “Not Wisest Way To Use Them” – Newell

February 4, 1977

Avastin improves lung cancer survival, opens options for new combinations. Details of Avastin risk vs. benefit to be released at ASCO annual meeting.

April 1, 2005

Adjuvant XELOX More Effective Than 5-FU/LV For Stage III Colon Cancer

January 29, 2010

FDA Approves Kytril For Post-Operative Nausea

October 25, 2002

NCI-Approved Clinical Trials

June 30, 2006